Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This Phase One pediatric trial seeks to take advantage of the susceptibility of neuroblastoma
to proteasome inhibitors, proven in vitro, along with the proven in vitro synergy of
bortezomib with irinotecan and the successful Phase One pediatric trials of bortezomib to
create a treatment using these two drugs in combination to treat refractory/recurrent
neuroblastoma in children and young adults 25 and under.
Phase:
Phase 1
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center